SCHEMBL16675394

SCHEMBL16675394

CCOC(=O)c1c(S(=O)(=O)N2CCOC(COc3cncc(-c4ccccc4)c3)C2)c2cc(Cl)ccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.42
EPHA2 P29317 2/20 0.38
KDR P35968 2/20 0.38
EPHB4 P54760 2/20 0.38
PTGDR2 Q9Y5Y4 6/20 0.36
CYP19A1 P11511 1/20 0.35
POLB P06746 1/20 0.35
ADAM17 P78536 1/20 0.35
DRD4 P21917 2/20 0.34
NOD2 Q9HC29 1/20 0.34
NOD1 Q9Y239 1/20 0.34
CHRNB1 P11230 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNB3 Q05901 1/20 0.34
PTGIR P43119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15295158 1.00 ACLY (0.42) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL16675380 0.94 ACLY (0.45) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL15295148 0.94 ACLY (0.45) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL16675385 0.92 ACLY (0.42) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL15295154 0.92 ACLY (0.42) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL4014930 0.91 ACLY (0.51) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL4318896 0.91 ACLY (0.51) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL15287441 0.89 ACLY (0.44) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL15287481 0.89 ACLY (0.42) ACLYEPHA2KDREPHB4PTGDR2
SCHEMBL15295335 0.87 ACLY (0.42) ACLYEPHA2KDREPHB4PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150119394-A1 Insulin-Like Growth Factor-1 Receptor Inhibitors MERCK SHARP & DOHME CORP. 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119394-A1 Insulin-Like Growth Factor-1 Receptor Inhibitors IGF1R, IGFBP1, INSR ACLY 1860/4885EPHA2 1559/4885KDR 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.